European Med-tech startup was working on finding new medications. To design a drug, they had to examine a vast range of molecules during the screening process. The process was expensive in terms of time and chemical resources used. And even if costs were high, it did not ensure a successful result.
Alphamoon team solved the issue by building a solution based on Deep Generative Models. It helped to reduce the initial group of molecules for the screening process (by a factor of 10). It led to a lower cost of time and other resources. Moreover, it increased hit precision of the screening process.